New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
10:08 EDTLCILannett does not expect study to significantly impact Digoxin sales
Lannett commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology, which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF study from the U.S. Department of Veterans Affairs healthcare system, the company said. "Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, CEO of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available. The company said it does not expect prescriptions of Digoxin to be significantly impacted by the findings of the JACC study. Digoxin currently represents less than 10 percent of the company’s net revenues." Bedrosian went on to say that the company has "implemented a comprehensive strategy to expand and diversify its product offering by developing products internally, forming strategic alliances and acquiring products complementary to its business."
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:29 EDTLCILannett launches Oxycodone Hydrochloride Oral Solution
Lannett Company announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price were approximately $43M. “We previously expected to begin marketing our Oxycodone Hydrochloride Oral Solution product in the second half of our fiscal year,” said Arthur P. Bedrosian, president and CEO of Lannett. “The earlier than anticipated launch combined with continued strong sales of our Digoxin product in the first quarter provide us with additional confidence to reaffirm our financial guidance for the fiscal 2015 full year.”
September 17, 2014
11:01 EDTLCIActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
September 16, 2014
07:55 EDTLCILannett voluntarily conducts internal review in response to CT AG inquiry
Subscribe for More Information
September 10, 2014
13:36 EDTLCILannett receives FDA approval for oxycodone hydrochloride oral solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use